Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
A. Oguz, M. Benroubi, K. Brismar, P. Melo, C. Morar, S.P. Cleall, J. Giaconia & H. Schmitt. (2013) Clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes in five countries: results from the TREAT study. Current Medical Research and Opinion 29:8, pages 911-920.
Read now
Read now
Katarina Raslova. (2010) An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog. Vascular Health and Risk Management 6, pages 399-410.
Read now
Read now
Jean-Pierre Le Floch. (2010) Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics. Diabetes, Metabolic Syndrome and Obesity 3, pages 197-213.
Read now
Read now
Articles from other publishers (17)
Sergei Pechenov, Himanshu Bhattacharjee, Daniel Yin, Sachin Mittal & J. Anand Subramony. (2017) Improving drug-like properties of insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery. Advanced Drug Delivery Reviews 112, pages 106-122.
Crossref
Crossref
A.-J. Scheen. (2016) Instauration d’une insulinothérapie chez le patient diabétique de type 2 en médecine générale : Comparaison de l’étude belge InsuStar avec quelques études françaises et internationales. Médecine des Maladies Métaboliques 10:4, pages 334-340.
Crossref
Crossref
Marcin Czech, Elżbieta Rdzanek, Justyna Pawęska, Olga Adamowicz-Sidor, Maciej Niewada & Michał Jakubczyk. (2015) Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis. BMC Endocrine Disorders 15:1.
Crossref
Crossref
Linong Ji, Shih-Tzer Tsai, Jay Lin & Sanjiv Bhambani. (2015) National Variations in Comorbidities, Glycosylated Hemoglobin Reduction, and Insulin Dosage in Asian Patients with Type 2 Diabetes: The FINE-Asia Registry. Diabetes Therapy 6:4, pages 519-530.
Crossref
Crossref
Philip D. Home, Marie-Paule Dain, Nick Freemantle, Ryuzo Kawamori, Martin Pfohl, Sandrine Brette, Valérie Pilorget, Werner A. Scherbaum, Giacomo Vespasiani, Maya Vincent & Beverley Balkau. (2015) Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents. Diabetes Research and Clinical Practice 108:2, pages 350-359.
Crossref
Crossref
Changyu Pan, Ping Han, Linong Ji, Qiuhe Ji, Juming Lu, Jing Lin, Jie Liu, Benli Su, Jingmei Shi & Penghua Wang. (2015) Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: Subgroup analysis of the SOLVE study 一天一次地特胰岛素对中国2型糖尿病患者体重的中性影响：SOLVE研究亚组分析. Journal of Diabetes 7:2, pages 222-230.
Crossref
Crossref
Ivan Ivanovich Dedov & Marina Vladimirovna Shestakova. (2014) Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues. Diabetes mellitus 17:4, pages 108-119.
Crossref
Crossref
Taner Damci, Rifat Emral, Anne Louise Svendsen, Tanzer Balkir & Jiten Vora. (2014) Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study. BMC Endocrine Disorders 14:1.
Crossref
Crossref
Etie S. Moghissi. (2014) Treating Patients With Diabetes of Long Duration: GLP-1 Receptor Agonists and Insulin in Combination. Journal of Osteopathic Medicine 114:s52, pages 22-29.
Crossref
Crossref
Stuart Ross, Grzegorz Dzida, Qiuhe Ji, Marcel Kaiser, Robert Ligthelm, Luigi Meneghini, Avideh Nazeri, Domingo Orozco‐Beltran, Changyu Pan & Anne Louise Svendsen. (2013) Safety of once‐daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice (在常规临床实践中使用口服降糖药治疗的2型糖尿病患者每日一次使用地特胰岛素治疗的安全性). Journal of Diabetes 6:3, pages 243-250.
Crossref
Crossref
K. Niswender, M. Piletic, H. Andersen, L. Conradsen Hiort & P. Hollander. (2013)
Weight change upon once‐daily initiation of insulin detemir with or without dietary intervention in overweight or obese insulin‐naïve individuals with type 2 diabetes: results from the
DIET
trial
. Diabetes, Obesity and Metabolism 16:2, pages 186-192.
Crossref
Crossref
Alexey Zilov, Nabil El Naggar, Siddharth Shah, Chunduo Shen & Jihad Haddad. (2013) Insulin detemir in the management of type 2 diabetes in non-Western countries: Safety and effectiveness data from the A1chieve observational study. Diabetes Research and Clinical Practice 101:3, pages 317-325.
Crossref
Crossref
Athena Philis-Tsimikas. (2013) Initiating Basal Insulin Therapy in Type 2 Diabetes: Practical Steps to Optimize Glycemic Control. The American Journal of Medicine 126:9, pages S21-S27.
Crossref
Crossref
Gillian M. Keating. (2012) Insulin Detemir. Drugs 72:17, pages 2255-2287.
Crossref
Crossref
Jeffrey S. Freeman. (2010) Are Analogue Insulins Superior to Human Insulin in Clinical Practice?. Current Diabetes Reports 10:3, pages 176-183.
Crossref
Crossref
Luigi Meneghini, Sara Artola, Salvatore Caputo, Taner Damci, Grzegorz Dzida, Marcel Kaiser, Kamlesh Khunti, Andreas Liebl, Robert Ligthelm, Alberto Maran, Domingo Orozco-Beltran, Stuart Ross & Jean-François Yale. (2010) Practical guidance to insulin management. Primary Care Diabetes 4, pages S43-S56.
Crossref
Crossref
Edith M. Heintjes, Trine L. Thomsen, Fernie J. A. Penning-van Beest, Torsten E. Christensen & Ron M. C. Herings. (2010) Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes. Advances in Therapy 27:4, pages 211-222.
Crossref
Crossref